Vaxfab Enterprises Limited has informed the exchanges that its board will meet on Saturday, May 30, 2026. The primary agenda of the meeting is to consider and approve the audited financial results of the company for the quarter and year ended on March 31, 2026.

In a regulatory filing, the company stated that the trading window for dealing in its securities by all designated persons has been closed since April 01, 2026. This closure will continue to remain in effect until 48 hours after the submission of the financial results for the quarter ended March 31, 2026.

Meeting Details

The board meeting is convened in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations. The approval of the audited financial results will mark the conclusion of the financial reporting for the fiscal year 2025-26.

Vaxfab Enterprises Limited, in a Board of Directors meeting held on May 11, 2026, approved the allotment of 19,50,348 equity shares of face value ₹10/- each at a price of ₹21.02/- per share, upon conversion of outstanding equity share warrants into fully paid-up equity shares on a preferential basis. The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Schedule III of the said Regulations. The board meeting commenced at 9.00 A.M. and concluded at 9.20 A.M.

Allotment Details

The equity shares were allotted upon exercise of outstanding equity share warrants, which had originally been issued by way of a preferential allotment. Each warrant carried the right to subscribe to one equity share per warrant at a total exercise price of ₹21.02/-, comprising ₹5.255/- paid at the time of allotment of warrants and ₹15.765/- payable at the time of conversion into equity shares. The allotted equity shares rank pari-passu in all respects with the existing equity shares of the company. The tenure of the warrants did not exceed 18 months from the date of their allotment.

The following table summarises the key parameters of this allotment:

Impact on Share Capital

Consequent to this allotment, the paid-up equity share capital of Vaxfab Enterprises increased to ₹25,46,89,250/- (Rupees Twenty-five crore forty-six lakh eighty-nine thousand two hundred fifty only), comprising 2,54,68,925 equity shares of face value ₹10/- each.

Investor-Wise Allotment Breakdown

The 19,50,348 equity shares were allotted to six investors upon conversion of their respective warrants. The warrant exercise amount was received at ₹15.765/- per warrant at the time of conversion. The table below provides a detailed investor-wise breakdown:

Regulatory Compliance

The allotment was carried out in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023. The requisite disclosures have been submitted to BSE Limited and The Calcutta Stock Exchange Limited. The allotment was approved and signed by Ravindra Ashokbhai Joshi, Managing Director (DIN: 10112296).